Recent clinical studies have focused on elgemtumab, also known as LJM716, a humanized antibody designed to interact with the receptor Siglec-9 target . This investigational compound demonstrates promising efficacy in preclinical models, particularly concerning hematological cancers . The process

A Deep Dive into the SGN-70 This therapeutic antibody represents a exciting method in tumor treatment, specifically targeting the CD22 antigen expressed on various leukemias and lymphomas. Developed by Seattle Genetics, it functions as an antibody-dependent c